Duchenne muscular dystrophy (DMD) is a recessive genetic disease on X chromosome, with a prevalence rate of 1/5 000 and a higher incidence in males. Its main clinical manifestation is progressive myasthenia; and advances in DMD treatment, including corticosteroid therapy, have improved the patients' function, quality of life, and life expectancy. In recent years, researchers have made further studies on its pathogenesis and treatment, including nuclear factor, adiponectin, up-regulation of dystrophy protein-related proteins, gene therapy, stem cell therapy, etc. In this paper, the pathogenesis, clinical manifestations, and treatment progress of this disease are reviewed.

Duchenne muscular dystrophy; Pathogenesis; Drug therapy; Gene therapy; Stem cell therapy